DGAT2 and metabolic dysfunction-associated steatohepatitis: In addition, the aforementioned DGAT2 and its corresponding antisense drug IONIS-DGAT2RX (ClinicalTrials.gov NCT03334214) are currently undergoing phase 2 clinical trials for the treatment of NASH (Loomba et al., 2020).